MétaCan
Menu
Back to cohort
Record W1497876949

Hsp90 and histone deactylase inhibitor have synergistic activity against synovial sarcoma.

2006· article· en· W1497876949 on OpenAlexaff
Anne Nguyen, Jefferson Terry, Suzanne Liu, Torsten O. Nielsen

Bibliographic record

VenueClinical Cancer Research · 2006
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicBeetle Biology and Toxicology Studies
Canadian institutionsUniversity of British Columbia
Fundersnot available
KeywordsSynovial sarcomaCancer researchHistone deacetylaseHistone deacetylase inhibitorCancerSarcomaSoft tissue sarcomaMalignancyMedicineBiologyPathologyInternal medicineHistone
DOInot available

Abstract

fetched live from OpenAlex

B50 Clinically-applicable Hsp90 and histone deacetylase inhibitors have independently been shown to suppress growth and induce apoptosis in synovial sarcoma; this study tests the hypothesis that such agents may be synergistic, which would permit increased efficacy while reducing dose and minimizing potential side effects. Synovial sarcoma is an aggressive soft tissue malignancy of unknown cellular origin, which typically affects young adults and often proves fatal. The chromosomal translocation t(X;18)(p11.2;q11.2) resulting in the fusion oncoprotein SYT-SSX is characteristic of this disease, but its function in oncogenesis is unclear. Synovial sarcoma exhibits an undifferentiated mesenchymal phenotype that suggests its malignant transformation involves dysfunctional cellular differentiation. The Hsp90 inhibitor 17AAG is being tested in clinical trials in a variety of cancers including leukemias, lymphomas, and sarcomas. Histone deacetylase inhibitors (including MS-275) are also currently involved in clinical trials of several cancers including leukemias and lymphomas and are considered to be promising new therapies for a wide range of cancers. Recently, we (Terry J et al. Clin Cancer Res 2005;11:5641) and others (Ito T et al. Cancer Lett 2005;224:311) have found that both 17AAG and histone deacetylase inhibitors, as single agents, are successful in arresting growth of synovial sarcoma in vitro and slowing growth in xenografts. We therefore tested combinations of 17AAG with the histone deacetylase inhibitor MS-275 by MTT proliferation assays and by Annexin V flow cytometry apoptosis assay, using established synovial sarcoma cell line models. Synergism was assessed by the median-effect principle of Chou and Talalay. As single agents, the IC50 for 17AAG is 2.1 uM and for MS275 is 4.5 uM at 24 hours in these assays. In synovial sarcoma cell line SYO-1, 50% reduction in MTT absorbance at 24 hours was achieved by a combination of 0.1 uM 17AAG with 0.25 uM MS-275. This result is nine times more effective than if the drugs were simply additive. Synergistic effects were still present at later assay time points, and in the synovial sarcoma cell line Fuji. These results show, for the first time, that 17AAG and histone deacetylase inhibitors are synergistic against synovial sarcoma in vitro and suggest that low dose combination therapies may be effective against this disease.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.010

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.103
GPT teacher head0.474
Teacher spread0.371 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2006
Admission routes1
Has abstractyes

Explore more

Same venueClinical Cancer ResearchSame topicBeetle Biology and Toxicology StudiesFrench-language works237,207